Repro Med Systems Inc (KRMD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Repro Med Systems Inc (KRMD) has a cash flow conversion efficiency ratio of 0.012x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($216.11K) by net assets ($18.05 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Repro Med Systems Inc stock valuation for the company's overall valuation and market capitalisation.
Repro Med Systems Inc - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how Repro Med Systems Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Repro Med Systems Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Repro Med Systems Inc ranked by their cash flow conversion efficiency. Explore KRMD cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
LONCOR GOLD INC.
F:LO5
|
N/A |
|
Tekna Holding AS
OL:TEKNA
|
0.062x |
|
Putnam Master Intermediate Income Trust
NYSE:PIM
|
0.019x |
|
LBS Bina Group Bhd
KLSE:5789
|
0.025x |
|
Eastern Communications Co Ltd B
SHG:900941
|
0.030x |
|
Nnit AS
CO:NNIT
|
0.064x |
|
Welldone Co
TWO:6170
|
0.088x |
|
Areeya Property Public Company Limited
BK:A
|
-0.302x |
Annual Cash Flow Conversion Efficiency for Repro Med Systems Inc (1996–2025)
The table below shows the annual cash flow conversion efficiency of Repro Med Systems Inc from 1996 to 2025. View latest Repro Med Systems Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $17.05 Million | $462.40K | 0.027x | +242.64% |
| 2024-12-31 | $16.81 Million | $-319.72K | -0.019x | +92.09% |
| 2023-12-31 | $20.35 Million | $-4.89 Million | -0.240x | -39.33% |
| 2022-12-31 | $31.33 Million | $-5.40 Million | -0.173x | -45.79% |
| 2021-12-31 | $36.50 Million | $-4.32 Million | -0.118x | -475.63% |
| 2020-12-31 | $36.16 Million | $-743.32K | -0.021x | -172.05% |
| 2019-12-31 | $11.24 Million | $320.62K | 0.029x | -82.72% |
| 2018-12-31 | $8.96 Million | $1.48 Million | 0.165x | +40.73% |
| 2017-12-31 | $7.67 Million | $899.91K | 0.117x | +336.21% |
| 2016-12-31 | $6.68 Million | $-331.62K | -0.050x | -117.56% |
| 2015-12-31 | $6.77 Million | $1.91 Million | 0.283x | +114.76% |
| 2014-12-31 | $6.27 Million | $826.10K | 0.132x | -28.37% |
| 2013-12-31 | $5.19 Million | $954.39K | 0.184x | +2.05% |
| 2012-12-31 | $4.36 Million | $784.79K | 0.180x | +14.10% |
| 2011-12-31 | $3.55 Million | $560.60K | 0.158x | -67.34% |
| 2010-12-31 | $2.13 Million | $1.03 Million | 0.483x | +30.72% |
| 2009-12-31 | $1.03 Million | $382.30K | 0.370x | -50.62% |
| 2008-12-31 | $705.09K | $528.18K | 0.749x | +483.59% |
| 2007-12-31 | $-602.26K | $117.61K | -0.195x | -247.35% |
| 2006-12-31 | $-645.83K | $-85.59K | 0.133x | -45.57% |
| 2005-12-31 | $-569.82K | $-138.75K | 0.243x | -51.70% |
| 2004-12-31 | $-380.26K | $-191.69K | 0.504x | +150.37% |
| 2003-12-31 | $-173.46K | $-34.92K | 0.201x | -32.76% |
| 2002-12-31 | $61.19K | $18.32K | 0.299x | +315.55% |
| 2001-12-31 | $337.38K | $-46.87K | -0.139x | +29.35% |
| 2000-12-31 | $694.45K | $-136.56K | -0.197x | -234.46% |
| 1999-12-31 | $657.91K | $96.22K | 0.146x | +171.80% |
| 1998-12-31 | $540.00K | $-110.00K | -0.204x | -15.43% |
| 1997-12-31 | $1.87 Million | $-330.00K | -0.176x | -266.50% |
| 1996-12-31 | $2.17 Million | $230.00K | 0.106x | -- |
About Repro Med Systems Inc
KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. The company offers the FREEDOM infusion systems to deliver therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating polyneuropath… Read more